PerkinElmer has signed an agreement to acquire US-based BioLegend, a life science antibodies and reagents provider, in a deal valued at about $5.25bn. BioLegend provides antibodies and reagents
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Moderna’s Covid-19 vaccine, Spikevax, for adolescents aged 12 to 17
Merck and Eisai have secured approval from the US Food and Drug Administration (FDA) for Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination to treat patients with certain types of
Pfizer and Arvinas have collaborated to co-develop and co-commercialise ARV-471, an investigational oral Protac estrogen receptor protein degrader. The estrogen receptor (ER) is a well-known disease driver in
AstraZeneca has completed the acquisition of biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn. The latest move comes after the receipt of clearance from the UK
Pfizer and BioNTech have signed a letter of intent with The Biovac Institute, the South African biopharmaceutical company, to jointly manufacture and distribute their Covid-19 Vaccine in the
McKesson Corporation, Cardinal Health and Amerisource Bergen Drug, the three largest US drug distributors, have agreed to pay up to $1.18bn to settle the ongoing opioid-related case with
Roche has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Ronapreve to treat mild to moderate Covid-19 patients. Designed to block SARS-CoV-2 infectivity, Ronapreve
Private equity firm Partners Group has agreed to acquire Pharmathen from an international investment firm BC Partners in a deal valued about $1.88bn (€1.6bn). Private pharma company, Pharmathen
GlaxoSmithKline (GSK) has announced plans to construct a new campus for biotechnology and early-stage life science companies in Stevenage, England. The company is looking for a development partner
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.